Bach David S
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
J Am Coll Cardiol. 2009 May 19;53(20):1852-4. doi: 10.1016/j.jacc.2008.09.023.
In 2007, the American Heart Association published a guideline statement dramatically changing its previous position on the use of antibiotic prophylaxis in patients at risk of infective endocarditis (IE). This year, these views were incorporated in an update of the 2006 American College of Cardiology/American Heart Association Guidelines for the Management of Patients With Valvular Heart Disease. The new recommendations represent a dramatic shift with regard to which patients should receive antibiotic prophylaxis for prevention of IE and for what procedures. The shift in recommendations is striking in that the recommendations are based not on new data, but on no data. (There are no large, prospective, randomized double-blind trials testing the efficacy of IE prophylaxis.) However, available data suggest that there may be no real risk associated with IE prophylaxis. Even if few cases of IE are successfully prevented using antibiotic prophylaxis, those few cases may represent a favorable risk-benefit ratio. On an individual basis, patients with organic heart valve disease who are trying to delay or avoid surgical intervention have something very real to risk if they develop IE, and a very real benefit if they avoid it. Pending data from prospective randomized trials, a strategy of individual decision-making by informed patients may be best.
2007年,美国心脏协会发表了一份指南声明,极大地改变了其先前对于感染性心内膜炎(IE)高危患者使用抗生素预防的立场。今年,这些观点被纳入了2006年美国心脏病学会/美国心脏协会瓣膜性心脏病患者管理指南的更新版中。新的建议在哪些患者应接受抗生素预防以预防IE以及针对何种手术方面代表了巨大转变。建议的转变令人惊讶,因为这些建议并非基于新数据,而是基于无数据(没有大型、前瞻性、随机双盲试验来测试IE预防的疗效)。然而,现有数据表明,IE预防可能并无真正风险。即使使用抗生素预防成功预防的IE病例很少,那些少数病例可能也代表了有利的风险效益比。就个体而言,患有器质性心脏瓣膜病且试图延迟或避免手术干预的患者,如果发生IE,将面临非常真实的风险,如果避免发生IE,则会有非常真实的益处。在获得前瞻性随机试验的数据之前,由明智的患者进行个体决策的策略可能是最佳的。